Key Takeaways:

  • Trump administration indefinitely delays BALANCE Model after Medicare Part D plans failed to meet 80% participation requirement by April 20 deadline
  • Medicare GLP-1 Bridge program extended through December 2027, offering $50 monthly copays for Wegovy and Zepbound
  • Major insurers including CVS Health/Aetna and UnitedHealth cited "notable challenges" in opting out of the program
  • Medicaid rollout of BALANCE Model continues as planned, with state applications due by July 2026

Medicare's GLP-1 Coverage Plan Hits Major Roadblock

The Trump administration indefinitely delayed a Medicare pilot program to cover weight-loss drugs after health insurance companies voiced concerns about participating, with CMS announcing on April 21, 2026, that the BALANCE Model will not be implemented in Medicare Part D in 2027 as originally planned.

The agency already knew by April 20 whether the 80 percent participation threshold had been cleared, and the speed of the next-day response indicates the miss was material. CMS reported that it did not meet the necessary threshold of sponsors and would indefinitely delay the pilot for Medicare.

Insurers had until April 20 to commit to the program. CVS Health, which owns Aetna, said it chose not to opt into the BALANCE program. On UnitedHealth's earnings call on April 21, a company official cited "notable challenges and outstanding questions" about the program.

What the BALANCE Model Would Have Accomplished

The Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model was designed to expand Medicare coverage for GLP-1 medications like Wegovy and Zepbound for weight loss – something Medicare has historically been prohibited from covering.

For the first time, coverage for weight-loss medications would have been available to Medicare beneficiaries with obesity who don't also have related health conditions such as diabetes or cardiovascular issues. Under the demonstration, as Medicare reduces the prices it pays to Eli Lilly and Novo Nordisk for GLP-1s to treat diabetes and cardiovascular disease, it would use the savings to pay for expanded coverage for GLP-1 drugs solely for weight loss.

BALANCE was announced less than six months before 2027 plan bids are due to CMS on June 1, 2026. Because GLP-1s for weight loss have never been covered under Part D, there is no existing claims data to reliably estimate how many Medicare beneficiaries may qualify under the model. Without this data, plan sponsors faced considerable uncertainty in accurately estimating their expected drug spend and setting appropriate beneficiary premiums with expanded GLP-1 coverage.

This tight timeline created additional pressure on insurers already grappling with the financial implications of covering expensive medications that could cost plans thousands per patient annually.

Bridge Program Becomes Extended Solution

Instead, the GLP-1 Bridge program will be extended through 2027. Medicare will offer GLP-1 weight-loss drugs through a bridge program from July 1 through Dec. 31, 2027, allowing enrollees to get weight-loss drugs at a flat $50 monthly copay.

The Medicare GLP-1 Bridge is a nationwide demonstration program that will be separate from Part D coverage, meaning Part D sponsors will not have to opt into the demonstration for eligible beneficiaries to gain access, nor will Part D sponsors bear any financial risk for costs. The change will allow Medicare beneficiaries access to certain GLP-1 medications "outside of the Medicare Part D benefit coverage and payment flow."

Medicare beneficiaries who meet eligibility criteria will have access to GLP-1 medications approved for weight reduction (Wegovy injections and oral tablets, and the Zepbound KwikPen) at a copayment of $50 per month. The Centers for Medicare & Medicaid Services will cover the remaining balance of the $245 monthly cost.

There's an important caveat: this doesn't count toward your True Out-of-Pocket (TrOOP) costs, and it's strictly for weight loss. If you already have coverage for a condition such as diabetes, you'll need to stay on your standard Part D plan for those medications.

Industry Response and Medicaid Moves Forward

An Eli Lilly spokesperson said the company supports the intent of the BALANCE pilot, and that the extension "provides an important opportunity to continue reaching patients who can benefit from GLP-1 therapies today." The company "advocates the long-term vision of the BALANCE model" but added the bridge program will reach patients who can benefit from GLP-1 drugs.

The extension of the bridge program through 2027 eases uncertainty around reimbursement for weight-loss drugs and blunts any near-term impact on demand, but an indefinite delay clouds long-term visibility on permanent integration into Medicare prescription drug plans. In the longer term, "once this obesity benefit is established, we believe it will be practically and politically difficult to roll back as we look toward 2028 and beyond," J.P.Morgan analyst Chris Schott said.

While rollout of the BALANCE Model in Medicare Part D remains paused, the model will continue to move forward in Medicaid. CMS will accept applications from state Medicaid agencies through July 31, 2026, with participation beginning between May 2026 and January 2027, depending on state readiness.

This split approach means that while Medicare beneficiaries face continued uncertainty about long-term coverage, Medicaid recipients in participating states may gain access to these medications through traditional coverage pathways.

What This Means for You

If you're a Medicare beneficiary hoping for GLP-1 coverage, the Bridge program launching July 1, 2026, may still provide access at $50 per month – significantly less than current out-of-pocket costs of $900-1,300 monthly for brand-name medications.

The key requirements will likely include meeting BMI thresholds and obtaining prior authorization from your doctor. However, if you use the Bridge program in 2026, you may need to switch Part D plans during the open enrollment period for 2027 to ensure coverage continuity. For participating beneficiaries to maintain Medicare coverage of their GLP-1 medication for obesity after the Medicare GLP-1 Bridge ends, they will need to be enrolled in a Part D plan that chooses to participate in any future version of the BALANCE Model.

For now, seniors have more certainty about access through 2027, even as the long-term Medicare coverage picture remains unclear. If you're exploring GLP-1 options before the Bridge program launches, consider working with experienced providers who understand these evolving coverage landscapes through our telehealth provider directory.

You can also start preparing by discussing your eligibility with your current healthcare provider and reviewing your current Part D plan's formulary to understand what coverage options might be available to you in 2028 and beyond.